TUSTIN, Calif., July 8 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today the launch of a new brand name for its DR-70 (FDP) in vitro diagnostic cancer test. With today's announcement, AMDL will manufacture, market, and sell DR-70 under the more consumer-friendly, trademarked brand name Onko-Sure(TM).
Coinciding with the adoption of the new Onko-Sure(TM) brand name, AMDL also announces the successful completion of its annual ISO inspection of its Tustin, CA-based manufacturing facilities and receivership of its International Regulatory Compliance Re-certification IS0 13485:2003 for the international production of its Onko-Sure(TM) IVD cancer test.
Mr. Douglas MacLellan, Chairman and CEO of AMDL stated, 'Over the past six months AMDL has been executing a very aggressive commercialization strategy for DR-70, which is progressing at a faster pace than originally expected. With several key distribution and collaboration partnerships under our belt, and more in the pipeline, we feel timing is optimal to establish a uniform and more consumer-friendly brand name for DR-70. The Onko-Sure(TM) identity represents a key milestone in AMDL's strategy for building and harmonizing an international business for this invaluable asset. We want Onko-Sure(TM) to become the undisputed #1 global brand for in vitro diagnostic cancer testing.'
In the Company's view, the Onko-Sure(TM) brand offers a clearer and more concise descriptor of AMDL's IVD test, communicating it as a high quality, innovative consumer cancer test. The Company is also instilling a new tag line -- 'The Power of Knowing' -- which communicates to cancer patients and their physicians the test is effective in assessing the importance of knowing whether a patient's cancer is progressing during treatment or is in remission.
AMDL's Onko-Sure(TM) in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).
